Sheila Annie Peters - Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations

22 Case Study 3Figure S3.1 Identifying higher in intestinal loss through hypothesis testing...

23 Case Study 4Figure S4.1 Modeling strategy to build a ciprofloxacin PBPK/PD model.Figure S4.2 Sensitivity analysis for process‐specific parameters and their r...

24 Case Study 5Figure S5.1 Impact of CYP3A inhibition by itraconazole and its derivatives o...Figure S5.2 Modeling strategy for evaluating the impact of itraconazole and ...Figure S5.3 Sensitivity analysis for process‐specific parameters and their r...

25 Case Study 6Figure S6.1 PBPK modeling is a powerful tool to explore and quantitatively p...Figure S6.2 Modeling strategy for evaluating the impact of rifampicin (DDI p...Figure S6.3 Sensitivity analysis for process‐specific parameters and their r...

26 Case Study 7Figure S7.1 Schematic representation of different CYP2D6 genotypes and the c...Figure S7.2 Modeling strategy for extrapolation of risperidone pharmacokinet...Figure S7.3 Sensitivity analysis for process‐specific parameters and their r...Figure S7.4 Plasma concentration‐time curve profiles (mean and standard devi...

27 Case Study 8Figure S8.1 Modeling strategy for extrapolation.Figure S8.2 Sensitivity analysis.

28 Case Study 9Figure S9.1 Structure of the physiologically based pharmacokinetic (PBPK) mo...Figure S9.2 Modeling strategy to extrapolate pharmacokinetics of metronidazo...Figure S9.3 Metronidazole plasma concentration–time profile after intravenou...

29 Case Study 10Figure S10.1 Modeling strategy for evaluating the impact of liver cirrhosis ...Figure S10.2 Simulation of the impact of liver cirrhosis on midazolam PK aft...Figure S10.3 Simulation of the impact of liver cirrhosis on lidocaine pharma...

30 Case Study 11Figure S11.1 Modeling strategy for evaluating the impact of CKD (chronic kid...Figure S11.2 Simulation of the impact of CKD (chronic kidney disease) on gen...

31 Case Study 12Figure S12.1 Schematic representation of in vitro in vivo correlation (IVIV...Figure S12.2 Sensitivity analysis plot of exposure shows that the only sign...Figure S12.3 Input and results of a virtual bioequivalence test by using a P...

1 COVER PAGE

2 TITLE PAGE

3 COPYRIGHT PAGE

4 DEDICATION PAGE

5 PREFACE TO THE SECOND EDITION

6 PREFACE TO THE FIRST EDITION

7 ACKNOWLEDGMENTS

8 ABOUT THE COMPANION WEBSITE

9 TABLE of Contents

10 BEGIN READING

11 APPENDICES

12 INDEX

13 WILEY END USER LICENSE AGREEMENT

1 iii

2 iv

3 v

4 xix

5 xx

6 xxi

7 xxiii

8 xxv

9 1

10 3

11 4

12 5

13 6

14 7

15 8

16 9

17 10

18 11

19 12

20 13

21 14

22 15

23 16

24 17

25 18

26 19

27 20

28 21

29 22

30 23

31 24

32 25

33 26

34 27

35 28

36 29

37 30

38 31

39 32

40 33

41 34

42 35

43 36

44 37

45 38

46 39

47 40

48 41

49 42

50 43

51 44

52 45

53 46

54 47

55 48

56 49

57 50

58 51

59 52

60 53

61 54

62 55

63 56

64 57

65 58

66 59

67 60

68 61

69 62

70 63

71 65

72 66

73 67

74 68

75 69

76 70

77 71

78 72

79 73

80 74

81 75

82 76

83 77

84 78

85 79

86 80

87 81

88 82

89 83

90 84

91 85

92 86

93 87

94 88

95 89

96 90

97 91

98 92

99 93

100 94

101 95

102 96

103 97

104 98

105 99

106 100

107 101

108 102

109 103

110 104

111 105

112 106

113 107

114 108

115 109

116 110

117 111

118 112

119 113

120 114

121 115

122 116

123 117

124 118

125 119

126 120

127 121

128 122

129 123

130 124

131 125

132 126

133 127

134 128

135 129

136 130

137 131

138 132

139 133

140 134

141 135

142 136

143 137

144 138

145 139

146 140

147 141

148 142

149 143

150 144

151 145

152 146

153 147

154 148

155 149

156 150

157 151

158 152

159 153

160 154

161 155

162 156

163 157

164 158

165 159

166 160

167 161

168 162

169 163

170 164

171 165

172 166

173 167

174 169

175 170

176 171

177 172

178 173

179 174

180 175

181 176

182 177

183 178

184 179

185 180

186 181

187 182

188 183

189 184

190 185

191 186

192 187

193 188

194 189

195 190

196 191

197 192

198 193

199 194

200 195

201 196

202 197

203 198

204 199

205 200

206 201

207 202

208 203

209 204

210 205

211 206

212 207

213 208

214 209

215 210

216 211

217 212

218 213

219 214

220 215

221 216

222 217

223 218

224 219

225 220

226 221

227 222

228 223

229 225

230 226

231 227

232 228

233 229

234 230

235 231

236 232

237 233

238 234

239 235

240 236

241 237

242 238

243 239

244 240

245 241

246 242

247 243

248 244

249 245

250 246

251 247

252 248

253 249

254 250

255 251

256 252

257 253

258 254

259 255

260 256

261 257

262 258

263 259

264 260

265 261

266 262

267 263

268 264

269 265

270 266

271 267

272 268

273 269

274 270

275 271

276 272

277 273

278 274

279 275

280 276

281 277

282 278

283 279

284 280

285 281

286 282

287 283

288 284

289 285

290 286

291 287

292 288

293 289

294 290

295 291

296 292

297 293

298 294

299 295

300 296

301 297

302 298

303 299

304 300

305 301

306 302

307 303

308 304

309 305

310 306

311 307

312 308

313 309

314 310

315 311

316 312

317 313

318 314

319 315

320 316

321 317

322 318

323 319

324 320

325 321

326 323

327 325

328 326

329 327

330 328

331 329

332 330

333 331

334 332

335 333

336 334

337 335

338 336

339 337

340 338

341 339

342 340

343 341

344 342

345 343

346 344

347 345

348 346

349 347

350 348

351 349

352 350

353 351

354 352

355 353

356 354

357 355

358 356

359 357

360 358

361 359

362 360

363 361

364 362

365 363

366 364

367 365

368 366

369 367

370 368

371 369

372 370

373 371

374 372

375 373

376 374

377 375

378 376

379 377

380 378

381 379

382 380

383 381

384 382

385 383

386 384

387 385

388 386

389 387

390 388

391 389

392 390

393 391

394 392

395 393

396 394

397 395

398 397

399 398

400 399

Читать дальше